Trial Profile
A population based cohort study of palivizumab exposure from Danish and Swedish children with risk of autoimmune diseases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Oct 2016
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 25 Oct 2016 New trial record
- 24 Sep 2016 Results published in the Pediatric Drugs.